Dr. Allison H. Bartlett, MD, MS, FAAP, is a pediatric infectious diseases specialist at the University of Chicago Medicine Comer Children’s Hospital. She grew up in Madison, Wisconsin and attended Princeton University with a major in molecular biology and a minor in Latin American Studies, graduating with Highest Honors in 1998. She graduated from Washington University School of Medicine in 2002 and completed her training in pediatrics and pediatric infectious diseases at Texas Children’s Hospital/Baylor College of Medicine in 2005 and 2008, respectively. After three years on the faculty at Texas Children’s, she was recruited in 2011 to the University of Chicago Medical Center to join the Section of Pediatric Infectious Diseases as well as the Infection Control and Prevention and Antimicrobial Stewardship Programs. She was promoted to Associate Professor in 2018.
First and foremost, Dr. Bartlett is an astute and caring clinician who strives to provide patient- and family-centered, evidence-based, high-value care to all her patients. She is a role model for trainees and colleagues of the value of interprofessional collaboration and communication.
In addition to her clinical and teaching responsibilities, she has several administrative roles. As the Associate Medical Director of Infection Control, she is the primary content expert for pediatric issues, and also participates in medical center-wide initiatives regardless of patient population. She created, developed and grew the pediatric Antimicrobial Stewardship program. In 2018, she handed over leadership of the pediatric Antimicrobial Stewardship Program to Dr. Madan Kumar, and serves as his mentor.
She has built on the expertise developed working with the Infection Control and Antimicrobial Stewardship programs and expanded the scope of her responsibilities to include departmental and institutional positions in quality improvement and patient safety. She was appointed Quality Chief for the Department of Pediatrics in 2014, and works with faculty, staff, and trainees to improve the quality, safety and efficiency of care that we provide to our patients. In 2017, she was named Executive Medical Director for High Reliability Care, and leads the institutional ‘High Reliability’ program to develop a system-wide approach to eliminate clinically unwarranted variation and provide perfect care for every patient at the highest value.
Dr. Bartlett lives in Hyde Park with her husband and their three sons. She and her family enjoy escaping the city and heading to the North Woods of Wisconsin in the summer for outdoor recreation: hiking, canoeing, swimming, fishing, sailing, and more.
Infectious Diseases Society of America Leadership Institute
Arlington, VA
- Leadership
2019
Epic (Physician Builder)
Verona, WI
- Physician Builder - Analytic
2018
Intermountain Healthcare
Salt Lake City
- Quality Improvement and Patient Safety
2017
Baylor College of Medicine
Houston, TX
MS - Clinical Investigation
2011
Baylor College of Medicine / Texas Children's Hospital
Houston ,TX
- Pediatric Infectious Diseases
2008
Baylor College of Medicine / Texas Children's Hospital
Houston, TX
- Pediatrics
2005
Washington University School of Medicine
St. Louis, MO
MD - Medicine
2002
Princeton University
Princeton, NJ
AB - Molecular Biology
1998
Use of Clinical Pathways Integrated into the Electronic Health Record to Address the COVID-19 Pandemic.
Bartlett AH, Makhni S, Ruokis S, Selling MK, Hall L, Umscheid CA, Kao CK. Use of Clinical Pathways Integrated into the Electronic Health Record to Address the COVID-19 Pandemic. Infect Control Hosp Epidemiol. 2022 Mar 22; 1-27.
PMID: 35314010
Hand Hygiene Compliance Rate During the COVID-19 Pandemic.
Makhni S, Umscheid CA, Soo J, Chu V, Bartlett A, Landon E, Marrs R. Hand Hygiene Compliance Rate During the COVID-19 Pandemic. JAMA Intern Med. 2021 07 01; 181(7):1006-1008.
PMID: 33900357
SHEA Pediatric Leadership Council commentary: Inpatient visitor considerations for pediatric patients during the coronavirus disease 2019 (COVID-19) pandemic.
Bartlett AH, Ravin KA, Rubin LG, McGrath C, de St Maurice A, Linam WM, Logan LK, Muller M, Caughell C, Ramirez-Avila L. SHEA Pediatric Leadership Council commentary: Inpatient visitor considerations for pediatric patients during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol. 2021 11; 42(11):1369-1371.
PMID: 34112274
Universal screening for Clostridioides difficile at an urban academic medical center.
Collison M, Murillo C, Marrs R, Bartlett A, Tesic V, Beavis KG, Landon E, Ridgway JP. Universal screening for Clostridioides difficile at an urban academic medical center. Infect Control Hosp Epidemiol. 2021 03; 42(3):351-352.
PMID: 32959739
Association Between Depth of Neutropenia and Clinical Outcomes in Febrile Pediatric Cancer and/or Patients Undergoing Hematopoietic Stem-cell Transplantation.
Alali M, David MZ, Danziger-Isakov LA, Bartlett AH, Petty LA, Schwartz T, Pisano J. Association Between Depth of Neutropenia and Clinical Outcomes in Febrile Pediatric Cancer and/or Patients Undergoing Hematopoietic Stem-cell Transplantation. Pediatr Infect Dis J. 2020 07; 39(7):628-633.
PMID: 32176187
A Multi-Centered Case-Case-Control Study of Factors Associated With Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Infections in Children and Young Adults.
Logan LK, Nguyen DC, Scaggs Huang FA, Qureshi NK, Charnot-Katsikas A, Bartlett AH, Zheng X, Hujer AM, Domitrovic TN, Marshall SH, Bonomo RA, Weinstein RA. A Multi-Centered Case-Case-Control Study of Factors Associated With Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Infections in Children and Young Adults. Pediatr Infect Dis J. 2019 05; 38(5):490-495.
PMID: 30169484
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemp Clin Trials. 2019 04; 79:98-103.
PMID: 30840903
SHEA neonatal intensive care unit (NICU) white paper series: Practical approaches to Clostridioides difficile prevention.
Sandora TJ, Bryant KK, Cantey JB, Elward AM, Yokoe DS, Bartlett AH. SHEA neonatal intensive care unit (NICU) white paper series: Practical approaches to Clostridioides difficile prevention. Infect Control Hosp Epidemiol. 2018 10; 39(10):1149-1153.
PMID: 30160646
Improved rates of antimicrobial stewardship interventions following implementation of the Epic antimicrobial stewardship module.
Pettit NN, Han Z, Choksi AR, Charnot-Katsikas A, Beavis KG, Tesic V, Bhagat P, Nguyen CT, Bartlett AH, Pisano J. Improved rates of antimicrobial stewardship interventions following implementation of the Epic antimicrobial stewardship module. Infect Control Hosp Epidemiol. 2018 08; 39(8):980-982.
PMID: 29950188
Physician Knowledge, Attitudes, and Practices Related to Chagas Disease in Tabasco, Mexico.
Berger BA, Bartlett AH, Jiménez-Hernández R, Trinidad Vázquez E, Galindo-Sevilla N. Physician Knowledge, Attitudes, and Practices Related to Chagas Disease in Tabasco, Mexico. Am J Trop Med Hyg. 2018 06; 98(6):1743-1747.
PMID: 29692299
Award for Excellence in Interdisciplinary Collaboration
University of Chicago Medicine
2019